• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

合成肽:疫苗开发的前景

Synthetic peptides: prospects for vaccine development.

作者信息

Milich D R

机构信息

Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, CA 92037.

出版信息

Semin Immunol. 1990 Sep;2(5):307-15.

PMID:2134015
Abstract

There is great interest in the use of synthetic peptides for vaccine purposes. Chemical synthesis guarantees an unlimited source of chemically stable protein at relatively low cost. Additionally, synthetic peptide antigens have been demonstrated to immunize T helper cells, cytotoxic T cells, and B cells which are reactive with representative native protein antigens. However, a number of obstacles to the use of peptide antigens have also been elucidated. The purpose of this review is to examine our current understanding of peptide antigens as immunogens, and the advantages and disadvantages of their use in vaccine design.

摘要

人们对将合成肽用于疫苗目的有着浓厚的兴趣。化学合成以相对较低的成本保证了化学稳定蛋白质的无限来源。此外,合成肽抗原已被证明可免疫与代表性天然蛋白质抗原发生反应的辅助性T细胞、细胞毒性T细胞和B细胞。然而,使用肽抗原的一些障碍也已被阐明。本综述的目的是审视我们目前对作为免疫原的肽抗原的理解,以及它们在疫苗设计中使用的优缺点。

相似文献

1
Synthetic peptides: prospects for vaccine development.合成肽:疫苗开发的前景
Semin Immunol. 1990 Sep;2(5):307-15.
2
Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines.
Semin Immunol. 1991 Jul;3(4):203-16.
3
Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.包含“混杂”T细胞表位的肽疫苗可绕过某些单倍型受限的免疫反应,并提供广谱免疫原性。
J Mol Recognit. 1993 Jun;6(2):81-94. doi: 10.1002/jmr.300060206.
4
Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.剖析肽在免疫反应中的作用:理论、实践及在疫苗设计中的应用
J Pept Sci. 2003 May;9(5):255-81. doi: 10.1002/psc.456.
5
Synthetic Plasmodium falciparum circumsporozoite peptides elicit heterogenous L3T4+ T cell proliferative responses in H-2b mice.合成的恶性疟原虫环子孢子蛋白肽在H-2b小鼠中引发异质性L3T4 + T细胞增殖反应。
J Immunol. 1986 Nov 1;137(9):2956-60.
6
Synthetic peptides: a modern approach to vaccination.合成肽:一种现代的疫苗接种方法。
Indian J Exp Biol. 1998 Sep;36(9):849-61.
7
Viral peptide immunogens: current challenges and opportunities.病毒肽免疫原:当前的挑战与机遇
J Pept Sci. 2007 Dec;13(12):776-86. doi: 10.1002/psc.896.
8
Design and development of synthetic peptide vaccines: past, present and future.合成肽疫苗的设计与开发:过去、现在与未来
Expert Rev Vaccines. 2007 Aug;6(4):591-603. doi: 10.1586/14760584.6.4.591.
9
Synthetic peptides as cancer vaccines.合成肽作为癌症疫苗。
Biopolymers. 2002;66(3):200-16. doi: 10.1002/bip.10258.
10
Tumor antigens and tumor vaccines: peptides as immunogens.肿瘤抗原与肿瘤疫苗:作为免疫原的肽
Semin Surg Oncol. 1996 Nov-Dec;12(6):446-53. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<446::AID-SSU10>3.0.CO;2-T.

引用本文的文献

1
Platform technology to generate broadly cross-reactive antibodies to α-helical epitopes in hemagglutinin proteins from influenza A viruses.用于产生针对甲型流感病毒血凝素蛋白中α-螺旋表位的广泛交叉反应性抗体的平台技术。
Biopolymers. 2016 Mar;106(2):144-159. doi: 10.1002/bip.22808.
2
Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.经鼻免疫微颗粒中鼠疫耶尔森菌 V 抗原 B 和 T 细胞表位顺序诱导的体液免疫应答和保护效力。
Med Microbiol Immunol. 2009 Nov;198(4):247-56. doi: 10.1007/s00430-009-0124-7. Epub 2009 Sep 25.
3
PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen.
第三代Sci-B-Vac疫苗接种后新生儿对前S1表位的识别及其与乙肝表面抗原抗体反应的关系。
Virol J. 2009 Jan 20;6:7. doi: 10.1186/1743-422X-6-7.
4
Recombinant avirulent salmonellae as oral vaccine carriers.重组无毒沙门氏菌作为口服疫苗载体。
Infection. 1992 Jan-Feb;20(1):1-8. doi: 10.1007/BF01704884.